REPLIMUNE GROUP, INC. (REPL) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 212.62M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 31.18M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -297.74M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $212.62M | (m) | $31.18M | $-297.74M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $221.18M | (m) | $32.27M | $-319.92M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $222.84M | (m) | $32.43M | $-325.91M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $218.75M | (m) | $34.02M | $-320.06M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $204.32M | (m) | $34.33M | $-294.68M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $189.45M | (m) | $35.04M | $-261.63M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $178.05M | (m) | $34.69M | $-241.06M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $171.84M | (m) | $34.29M | $-231.58M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $177.50M | (m) | $34.75M | $-236.49M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $174.96M | (m) | $34.13M | $-234.77M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $170.34M | (m) | $33.12M | $-229.01M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $157.75M | (m) | $31.91M | $-214.10M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $137.49M | (m) | $29.78M | $-191.85M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $126.53M | (m) | $28.13M | $-177.08M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $110.31M | (m) | $26.98M | $-156.07M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $99.40M | (m) | $25.88M | $-144.14M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $90.47M | (m) | $25.20M | $-131.81M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $79.55M | (m) | $24.25M | $-118.31M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $74.03M | (m) | $21.95M | $-108.51M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $69.00M | (m) | $19.08M | $-99.09M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $63.15M | (m) | $15.57M | $-89.50M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $56.75M | (m) | $11.79M | $-79.95M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $51.72M | (m) | $10.12M | $-74.16M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $49.34M | (m) | $9.42M | $-70.55M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $43.46M | (m) | $8.40M | $-63.12M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $38.76M | (m) | $7.74M | $-56.20M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $32.99M | (m) | $6.84M | $-47.64M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $28.90M | (m) | $5.38M | $-41.11M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $25.69M | (m) | $4.32M | $-35.97M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $22.17M | (m) | $2.73M | $-30.95M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $13.52M | (m) | $812.00K | $-19.23M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $6.94M | (m) | $208.00K | $-9.65M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |